Litcius/Paper detail

VGLL3 activates inflammatory responses by inducing interleukin‐1α secretion

Yuki Takakura, Naoto Hori, Natsumi Terada, Moeka Machida, Naoto Yamaguchi, Hiroyuki Takano, Noritaka Yamaguchi, Noritaka Yamaguchi, Noritaka Yamaguchi

2021The FASEB Journal23 citationsDOI

Abstract

Vestigial-like family member 3 (VGLL3), a member of the vestigial-like family, is a cofactor of the TEA-domain-containing transcription factor (TEAD). Although elevation in VGLL3 expression is associated with inflammatory diseases, such as inflammatory sarcomas and autoimmune diseases, the molecular mechanisms underlying VGLL3-mediated inflammation remain largely unknown. In this study, we analyzed the relationship between elevated VGLL3 expression and the levels of NF-κB, a transcription factor that plays a pivotal role in inflammation. NF-κB was found to be activated in a cell line stably expressing VGLL3. Mechanistically, VGLL3 was shown to promote the expression and secretion of the potent NF-κB-activating cytokine interleukin (IL)-1α, probably through its association with TEADs. As VGLL3 is a target of transforming growth factor β (TGF-β) signaling, we analyzed IL-1α induction upon TGF-β stimulation. TGF-β stimulation was observed to induce IL-1α secretion and NF-κB activation, and VGLL3 was associated with this phenomenon. The TGF-β transcription factors Smad3 and Smad4 were shown to be necessary for inducing VGLL3 and IL-1α expression. Lastly, we found that VGLL3-dependent IL-1α secretion is involved in constitutive NF-κB activation in highly malignant breast cancer cells. Collectively, the findings suggested that VGLL3 expression and TGF-β stimulation activate the inflammatory response by inducing IL-1α secretion.

Topics & Concepts

SecretionTranscription factorTransforming growth factorInflammationBiologyCytokineNF-κBCell biologyStimulationSignal transductionInterleukinCancer researchImmunologyEndocrinologyGeneGeneticsGenetic factors in colorectal cancerCancer-related molecular mechanisms researchIL-33, ST2, and ILC Pathways